Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | RXRB | P28702 | 2/20 | 0.50 |
| ▸ | RXRG | P48443 | 2/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29718989 | 1.00 | RXRA (0.50) | RXRARXRBRXRGMRGPRX4FFAR1 | |
| Trifluoroacetic Acid SCHEMBL5769358 | 0.95 | FFAR1 (0.47) | RXRARXRBRXRGMRGPRX4FFAR1 | |
| SCHEMBL1775542 | 0.86 | ALDH1A1 (0.52) | RXRARXRBRXRGMRGPRX4FFAR1 | |
| SCHEMBL30201250 | 0.86 | ALDH1A1 (0.52) | RXRARXRBRXRGMRGPRX4FFAR1 | |
| SCHEMBL31434971 | 0.85 | DAO (0.46) | MRGPRX4DAOP2RX7ALDH1A1KCNJ5 | |
| SCHEMBL4007916 | 0.83 | FFAR1 (0.58) | RXRARXRBRXRGMRGPRX4FFAR1 | |
| SCHEMBL3135089 | 0.82 | RXRA (0.53) | RXRARXRBRXRGALDH1A1PSEN1 | |
| SCHEMBL835012 | 0.81 | MAPT (0.51) | MRGPRX4DAOP2RX7ALDH1A1KCNJ5 | |
| SCHEMBL3741058 | 0.81 | POLQ (0.61) | RXRARXRBRXRGPSEN1PSEN2 | |
| SCHEMBL30530542 | 0.81 | IDO1 (0.51) | RXRARXRBRXRGFFAR1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103113219-A | Synthetic method of 2-chlorine-4-trifluoromethyl benzoic acid | UNIV HEILONGJIANG | 2013-05-22 | — | — | CN | claimed |
| US-11524938-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| EP-3270926-B1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3763704-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2021-01-13 | — | — | EP | disclosed |
| US-10844016-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-11-24 | — | — | US | disclosed |
| EP-3458443-B1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma AG (DE) | 2020-08-19 | — | — | EP | disclosed |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-04-25 | — | — | US | disclosed |
| EP-3458443-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| EP-1497277-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | NOVARTIS AG (CH) | 2004-05-13 | — | — | US | disclosed |
| WO-2003089422-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| US-6620838-B1 | Anticarcinogenic, antimestasis, and antiarthritic agents; osteoporosis and endometriosis treatment | SIGNAL PHARMACEUTICALS, INC. | 2003-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | RXRA 351/4885RXRB 499/4885RXRG 608/4885 |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | RXRA 351/4885RXRB 499/4885RXRG 608/4885 |
| US-11524938-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | RXRA 351/4885RXRB 499/4885RXRG 608/4885 |
| US-10844016-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | RXRA 351/4885RXRB 499/4885RXRG 608/4885 |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | RXRA 3818/4885RXRB 3646/4885RXRG 4100/4885 |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | RXRA 605/4885RXRB 638/4885RXRG 705/4885 |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | ESR2, CYP19A1, ESRRA | RXRA 221/4885RXRB 284/4885RXRG 273/4885 |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | RXRA 474/4885RXRB 746/4885RXRG 744/4885 |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | ESR2, ESRRA, ESR1 | RXRA 161/4885RXRB 160/4885RXRG 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.